Boston-based biotech Vertex Pharmaceuticals will end a late-stage clinical study testing a two-drug combination therapy on cystic fibrosis patients after an independent board concluded the treatment wasn’t showing meaningful benefit.
The study combined Vertex's drug candidate, called VX-661, with its approved drug, Kalydeco, and was targeting patients with two separate genetic mutations linked to CF.
VX-661 is Vertex’s lead development drug, which the company is using in combination with other approved and experimental meds to treat CF patients with different mutations. The drugmaker hopes to test this drug in a three-drug combination in the future.
Read the Boston Globe article